問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Endocrinology

更新時間：2023-09-19

黃禹堯Huang, Yu-Yao
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

  • yyh@cgmh.org.tw

Recruiting Trial

0Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

黃禹堯

List

30Cases

2007-07-01 - 2008-10-31

Phase IV

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2011-07-01 - 2012-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2009-04-01 - 2011-12-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2022-12-09 - 2029-06-30

Phase III

Active
Randomized, Double-blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy, Safety And Immunogenicity of Vaccination With ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years

  • Condition/Disease

    Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention

  • Test Drug

    ExPEC9V

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2010-01-01 - 2013-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2024-11-05 - 2027-02-02

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting5Sites

2022-04-05 - 2024-09-30

Phase III

Completed
A 52-week study comparing the efficacy and safety of once weekly IcoSema and once weekly semaglutide, both treatment arms with or without oral anti-diabetic drugs, in participants with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist. COMBINE 2

  • Condition/Disease

    Type 2 Diabetes

  • Test Drug

    IcoSema

Participate Sites
5Sites

Not yet recruiting4Sites

Terminated1Sites

2020-10-01 - 2024-12-31

Phase III

Completed
Effects of Semaglutide on Functional Capacity in Patients With Type 2 Diabetes and Peripheral Arterial Disease

  • Condition/Disease

    Diabetes Mellitus, Type 2/Peripheral Arterial Disease

  • Test Drug

    Semaglutide 1.34 mg/ml / placebo

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting1Sites

Terminated4Sites

2019-08-01 - 2025-02-28

Phase III

Completed
Semaglutide cardiovascular outcomes trial in patients with type 2 diabetes (SOUL)

  • Condition/Disease

    Type 2 diabetes

  • Test Drug

    Semaglutide Tablets 3 mg / 7 mg / 14 mg

Participate Sites
3Sites

Terminated3Sites

2008-10-01 - 2010-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB